DHL Group is scaling up its dedicated Airfreight Cold Chain Network to strengthen its Life Sciences & Healthcare logistics operations. Backed by a €2 billion strategic investment in DHL Health Logistics, the expansion provides end-to-end visibility for temperature-sensitive cargo, including vaccines, biologics, and cell and gene therapies.
The first major corridor in this expanded network connects Brussels (BRU) directly to Cincinnati (CVG). This route strategically links one of Europe’s leading life sciences clusters with the US Midwest, a major pharmaceutical hub.
- Direct Routing: By avoiding congested coastal gateways, DHL offers a direct, temperature-controlled lane for time-critical, high-value shipments.
- Specialised Infrastructure: Operations in Brussels are supported by 45,000 sqm of pharma-dedicated space at BRUcargo, ensuring clinical-grade handling.
To service this new route, DHL has deployed a dedicated Boeing 777 freighter flying under the new “DHL Health Logistics” livery. This aircraft guarantees predictable, controlled capacity on a critical trade lane.